Clinical Trial Search

Primary: Change in Lung Clearance Index 2.5 (LCI2.5) — 0.20; -0.46 lung clearance index

Primary: Number Of Participants Reporting Severe Treatment-Emergent Adverse Events (TEAE) — 50 participants

Primary: Kaplan Meier Estimate for Disease Free Survival (DFS) According to the Independent Radiological Review Committee — 19.4; 18.8 months — p=0.1824

Primary: Absolute Change From Baseline in Mean Noninflammatory Lesion Count to Week 12 — -17.8; -10.6 lesion count — p=<0.001

Primary: Number of Eyes With at Least 5-letter Decrease in E-ETDRS Visual Acuity Letter Score From Baseline — 33; 36; 39 Eyes

Primary: Incidence of Cardiovascular Mortality and Morbidity — 0.034050; 0.032759 Event per Patient Years of Followup

Primary: The Proportion of Subjects Having a Rescue-free Bowel Movement (RFBM) Within 4 Hours After the First Injection. — 79.2; 4.3 percentage of participants — p=<0.0001

Primary: Change From Baseline In Young-Mania Rating Scale (YMRS) Score At Week 3 — -12.3; -10.7 units on a scale — p==0.1011

Primary: Change From Baseline in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) — -3.2; -3.7 Score on a Scale — p=0.4421

Primary: Psoriasis Area and Severity Index (PASI) 75 (Multiple Imputation) — 112; 254; 6 Participants — p=<0.0001

Primary: Change in HbA1c (Week 26) — -1.1; -1.7; -1.7; -1.4 Percentage point of HbA1c — p=<0.0001

Primary: Number of Treatment-emergent Adverse Events (TEAEs) — 330; 350; 324; 178 Events

Primary: Mean Weekly Spontaneous Bowel Movements (SBMs) Per Month — 1.4; 4.9; 4.9; 5.0 Weekly SBMs

Primary: Overall Survival (PP Population) — 30.2; 26.1 months — p=0.1983

Primary: Percentage of Participants With Adverse Events — 156; 79; 95; 38 Participants